rHEALTH Targets $323 Billion Diagnostics Market with NASA-Tested Blood Testing Tech

rHEALTH is attempting to disrupt the global blood diagnostics market with a portable, lab-quality testing device originally designed for use on the International Space Station (ISS). The technology aims to address a critical gap in healthcare access, as the World Health Organization estimates that 4.5 billion people globally lack timely access to diagnostic testing. The rHEALTH ONE system allows for self-collected blood samples to be processed in as little as 20 minutes. This capability is particularly relevant for the 194 million U.S. adults managing chronic conditions who often face delays in care due to traditional lab processing times and interpretation delays. The platform is protected by 17 U.S. patents covering its device architecture and diagnostic algorithms. It has received over $20 million in non-dilutive funding and has established strategic partnerships with major institutions, including the Mayo Clinic, AstraZeneca, and Massachusetts General Hospital. From a commercial perspective, the company is targeting a total addressable market of $323 billion, with a specific focus on a $16.2 billion hematology diagnostics segment. rHEALTH intends to generate revenue through a combination of device sales, disposable test cartridges, and software subscriptions. The company is currently targeting FDA registration within the next 12 months. It is currently raising capital through a Reg CF offering to further its goal of decentralizing diagnostic care.